Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexa Bodman

Neurological Surgery Austin, TX Medical Doctor

NPI 1861783144 CMS profile 5618385

3000 N Ih 35 Ste 600, Ste 600, Austin, TX 78705

Open in the dashboard

General payments

$10,044

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexa Bodman of Austin, TX is reported in the CMS Open Payments database as having received $10,044 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,477 40
2024 General $859 19
2023 General $529 12
2022 General $462 12
2021 General $1,181 25
2020 General $2,330 21
2019 General $1,207 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexa Bodman
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Alexa Bodman were reported at $3,477. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Alexa Bodman Neurological Surgery median Middle half National median
2019 $1,207 $582 $138–$3,006 $163
2020 $2,330 $294 $76–$2,174 $114
2021 $1,181 $387 $105–$2,432 $132
2022 $462 $542 $139–$2,989 $149
2023 $529 $534 $145–$2,697 $160
2024 $859 $574 $155–$3,046 $164
2025 $3,477 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. icotec Medical Inc. $1,802 11 payments
  2. Medtronic USA, Inc. $1,750 19 payments
  3. Medtronic, Inc. $1,683 35 payments
  4. Stryker Corporation $1,362 24 payments
  5. Alphatec Spine, Inc $1,289 7 payments
  6. Abbott Laboratories $648 11 payments
  7. DePuy Synthes Sales Inc. $622 14 payments
  8. Foundation Medicine, Inc. $147 2 payments
  9. Providence Medical Technology, Inc. $134 1 payment
  10. Integra LifeSciences Corporation $110 5 payments
  11. Other $497 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,566 135 payments
  2. Travel and Lodging $2,478 8 payments
Products named General payments · program years 2019–2025
  1. CD HORIZON $1,228 14 payments
  2. Other - Miscellaneous $1,195 6 payments
  3. N/A $824 20 payments
  4. KONG-TL VBR E, EXPANDABLE BODY, L, 19 MM X 27 - 37 MM $508 4 payments
  5. VADER PEDICLE SYSTEM, ROD, CARBON/PEEK, CURVED, 6.0 R450 X 200 MM $508 4 payments
  6. KONG-TL VBR, END PLATE, RECTANGULAR, M AND SCREW, 12 X 33 MM $508 4 payments
  7. KONG-TL VBR, END PLATE, ROUND, L AND SCREW, 12 X 43 MM $508 4 payments
  8. VADER PEDICLE SYSTEM 6.0, SCREW, CARBON/PEEK, POLYAX., FEN., O 5.5 X 45 MM $508 4 payments
  9. CAPRI CORPECTOMY CAGE SYSTEM $424 7 payments
  10. O-ARM-ST $362 4 payments
  11. Other $5,524 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

31

Median for Neurosurgery: 83

Drug cost

$308

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 14 $197
Gabapentin Generic 17 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$38,137

Medicare's payments for the services billed

Medicare patients

123

Average age 75

Services billed

201

63 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Ischemic heart disease 37%
Diabetes 31%
Depression 28%
Atrial fibrillation 24%
Cancer 23%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record